Outsourcing

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Articles

The more pharma science and technology change, the more business and policy concerns stay the same.

Pharma’s Past Serves as Prologue to Its Future

Cambrex announces expansions of its North Carolina API pilot plant and Kalskoga, Sweden large-scale manufacturing facility.


Cambrex Increases API Capacity in US, Europe

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Kathleen A. Estes, PhD, is director of research communications atBioPlan Associates, Inc. She is an experienced market research and data trends analyst, author, and editor, kestes@bioplanassociates.com.

Although widespread adoption of continuous bioprocessing has been slow, some processes have been an exception.

Update on Continuous Bioprocessing: From the Industry’s Perception to Reality

Catalent has signed an agreement with Therachon to support preclinical and clinical development of TA-46, a novel protein being developed to treat achondroplasia.

Catalent Biologics Collaborates with Therachon to Develop Novel Protein Therapy for Achondroplasia

The company invested approximately $26 million to update its sterile pharmaceutical and development service suites.


Patheon Completes Expansion at Greenville Facility

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

CMOs may be gaining as strategic partners to large bio/pharma companies, but they have a much harder path to navigate.

CMOs and CROs Have Different Trajectories

Caladrius is selling the remaining percentage of the subsidiary in order to focus on cell therapy development.

Hitachi Chemical Purchases PCT From Caladrius Biosciences

Brian Keesee is Executive Director for North America Operations, PCI Clinical Services.

Cold-chain requirements and the tight logistical windows needed for cell and gene therapies demand a focus on early communication and risk mitigation.

Careful, Early Cold-Chain Planning is Crucial for New Biologics

Vetter expanded visual inspection facilities and controlled-temperature storage at its Ravensburg Vetter West facility in Germany.

Vetter Starts Operations in Its Center for Visual Inspection and Logistics

Catalent announces a development agreement with JOT to evaluate softgel options for a resveratrol drug candidate.

Contract Manufacturing Services